Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2009 | 4 | 2 | 164-170
Tytuł artykułu

Benefit of antibiotic therapy on pouchitis after ileal pouch anal anastomosis: A systematic review and meta-analysis of clinical trials

Treść / Zawartość
Warianty tytułu
Języki publikacji
The aim of the study was to evaluate and collect current evidence on the effect of antibiotics in pretreatment of pouchitis after restorative ileal pouch anal anastomosis (IPAA). Pubmed, Embase, Web of Science, Scopus, and Cochrane Library databases were searched between 1966 and July 2008; and relevant clinical trials extracted, reviewed, and validated according to the study protocol. The outcome of interest was clinical improvement after treatment. Nine randomized, placebo-controlled clinical trials were found relevant and studied but 3 of them with 70 patients were entered into meta-analysis. Pooling of the results from these trials yielded an odds ratio of 15.96 with a 95% CI of 4.20–60.70, indicating a significant OR (p<0.0001) in treatment group in comparison to the placebo group. In conclusion, the meta-analysis confirms benefit of antibiotics in management of pouchitis after IPAA operation.

Opis fizyczny
  • Division of Neurology, Institute of Medical Sciences, University of Toronto, Toronto, M5S 1A8, Canada
  • Food and Drug Affairs, and Food & Drug Laboratory Research Center, Ministry of Health & Medical Education, Tehran, 1314715311, Iran
  • Baharan Coloproctology Surgical Clinic, Tehran, 1516633115, Iran
  • Baharan Coloproctology Surgical Clinic, Tehran, 1516633115, Iran
  • Faculty of Pharmacy, and Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, 1417614411, Iran,
  • [1] Pricolo V.E., Ileal pouch-anal anastomosis: the ideal operation for ulcerative colitis and adenomatous polyposis coli? R. I. Med., 1994, 77, 382–384
  • [2] Blumberg D., Beck D.E., Surgery for ulcerative colitis, Gastroenterol. Clin. North Am., 2002, 31, 219–235 [Crossref]
  • [3] Aziz O., Athanasiou T., Fazio V.W., Nicholls R.J., Darzi A.W., Church J., et al., Meta-analysis of observational studies of ileorectal versus ileal pouch-anal anastomosis for familial adenomatous polyposis, Br. J. Surg., 2006, 93, 407–417[Crossref]
  • [4] Keighley M.R., Review article: the management of pouchitis. Aliment. Pharmacol. Ther., 1996, 10, 449–457[Crossref]
  • [5] Nicholls R.J., Belliveau P., Neill M., Wilks M., Tabaqchali S., Restorative proctocolectomy with ileal reservoir: a pathophysiological assessment, Gut, 1981, 22, 462–468[Crossref]
  • [6] Zuccaro G.Jr., Fazio V.W., Church J.M., Lavery I.C., Ruderman W.B., Farmer R.G., Pouch ileitis, Dig. Dis. Sci., 1989, 34, 1505–1510[Crossref]
  • [7] Tytgat G.N., van Deventer S.J., Pouchitis, Int. J. Colorectal Dis., 1988, 3, 226–228[Crossref]
  • [8] Simchuk E.J., Thirlby R.C., Risk factors and true incidence of pouchitis in patients after ileal pouchanal anastomoses, World J. Surg., 2000, 24, 851–856[Crossref]
  • [9] Kmiot W.A., Youngs D., Tudor R., Thompson H., Keighley M.R., Mucosal morphology, cell proliferation and faecal bacteriology in acute pouchitis, Br. J. Surg. 1993, 80, 1445–1449[Crossref]
  • [10] Rahimi R., Nikfar S., Rezaie A., Abdollahi M., A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn’s disease, Clin. Ther., 2006, 28, 1983–1988[Crossref]
  • [11] Rahimi R., Nikfar S., Rezaie A., Abdollahi M., A metaanalysis of antibiotic therapy for active ulcerative colitis, Dig. Dis. Sci., 2007, 52, 2920–2925[Crossref][WoS]
  • [12] Baker D.E., Rifaximin: a nonabsorbed oral antibiotic, Rev. Gastroenterol. Disord., 2005, 5, 19–30
  • [13] Ewaschuk J.B., Tejpar Q.Z., Soo I., Madsen K., Fedorak R.N., The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease, Curr. Gastroenterol. Rep., 2006, 8, 486–498[Crossref]
  • [14] Gionchetti P., Rizzello F., Lammers K.M., Morselli C., Sollazzi L., Davies S., et al., Antibiotics and probiotics in treatment of inflammatory bowel disease, World J. Gastroenterol., 2006, 12, 3306–3313
  • [15] Gionchetti P., Rizzello F., Venturi A., Ugolini F., Rossi M., Brigidi P., et al., Antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach, Eur. Rev. Med. Pharmacol. Sci., 1999, 3, 27–30
  • [16] Sachar D.B., How do you treat refractory pouchitis and when do you decide to remove the pouch? Inflamm. Bowel Dis., 1998, 4, 165–166[Crossref]
  • [17] Sandborn W.J., McLeod R., Jewell D.P., Medical therapy for induction and maintenance of remission in pouchitis: a systematic review, Inflamm. Bowel Dis. 1999, 5, 33–39 [Crossref]
  • [18] Madden M.V., McIntyre A.S., Nicholls R.J., Doubleblind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis, Dig. Dis. Sci., 1994, 39, 1193–1196[Crossref]
  • [19] Sambuelli A., Boerr L., Negreira S., Gil A., Camartino G., Huernos S., et al., Budesonide enema in pouchitis-a double-blind, double-dummy, controlled trial, Aliment. Pharmacol. Ther. 2002, 16, 27–34[Crossref]
  • [20] Shen B., Fazio V., Remzi F., Bennett A., Lopez R., Brzezinski A., et al., Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis, Dis. Col. Rectum., 2007, 50, 498–508[Crossref][WoS]
  • [21] Isaacs K.L., Sandler R.S., Abreu M., Picco M.F., Hanauer S.B., Bickston S.J., et al., Rifaximin for the treatment of active pouchitis: A randomized, double-blind, placebo-controlled pilot study, Inflamm. Bowel Dis., 2007, 13, 1250–1255[Crossref]
  • [22] Shen B., Achkar J.P., Lashner B.A., Ormsby A.H., Remzi F.H., Brzezinski A., et al., A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis, Inflamm. Bowel Dis., 2001, 7, 301–305[Crossref]
  • [23] Nygaard K., Bergan T., Bjorneklett A., Hoverstad T., Lassen J., Aase S., Topical metronidazole treatment in pouchitis, Scand. J. Gastroenterol., 1994, 29, 462–467[Crossref]
  • [24] Egger M., Smith G.D., Phillips A.N., Meta-analysis: principles and procedures, B. M. J., 1997, 315, 1533–1537
  • [25] Abdelrazeq A.S., Kelly S.M., Lund J.N., Leveson S.H., Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis, Colorectal Dis., 2005, 7, 182–186[Crossref]
  • [26] Abitbol V., Chaussade S., Pouchitis after ileal pouchanal anastomosis. Gastroenterol. Clin. Biol., 1997, 21, 299–304
  • [27] Becker J.M., Stucchi A.F., Bryant D.E., How do you treat refractory pouchitis and when do you decide to remove the pouch? Inflamm. Bowel Dis., 1998, 4, 167–169[Crossref]
  • [28] Gerard L., Garey K.W., DuPont H.L., Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections, Expert. Rev. Anti. Infect. Ther., 2005, 3, 201–211[Crossref]
  • [29] Gionchetti P., Amadini C., Rizzello F., Venturi A., Poggioli G., Campieri M., Diagnosis and treatment of pouchitis, Best Pract. Res. Clin. Gastroenterol., 2003, 17, 75–87[Crossref]
  • [30] Mimura T., Rizzello F., Helwig U., Poggioli G., Schreiber S., Talbot I.C., et al., Four-week openlabel trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis, Aliment. Pharmacol. Ther., 2002, 16, 909–917[Crossref]
  • [31] Madiba T.E., Bartolo D.C., Pouchitis following restorative proctocolectomy for ulcerative colitis: incidence and therapeutic outcome. J. R. Coll. Surg. Edinb., 2001, 46, 334–337
  • [32] Gionchetti P., Rizzello F., Venturi A., Ugolini F., Rossi M., Brigidi P., et al., Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis, Aliment. Pharmacol. Ther., 1999, 13, 713–718[Crossref]
  • [33] Shen B., Remzi F.H., Lopez A.R., Queener E., Rifaximin for maintenance therapy in antibioticdependent pouchitis, BMC Gastroenterol., 2008, 23, 26[Crossref][WoS]
  • [34] Gionchetti P., Rizzello F., Helwig U., Venturi A., Lammers K.M., Brigidi P., et al., Prophylaxis of pouchitis onset with probiotic therapy: a doubleblind, placebo-controlled trial, Gastroenterology, 2003, 124, 1202–1209[Crossref]
  • [35] Elahi B., Nikfar S., Derakhshani S., Vafaie M., Abdollahi M., Benefit of probiotics in the control of pouchitis in patients underwent ileal pouch anal anastomosis operation; A meta-analysis of controlled clinical trials, Dig. Dis. Sci., 2007, 53, 1278–1284[WoS][Crossref]
  • [36] Sambuelli A., Boerr L., Negreira S., Gil A., Camartino G., Huernos S., et al., Budesonide enema in pouchitis-a double-blind, double-dummy, controlled trial, Aliment. Pharmacol. Ther., 2002, 16, 27–34[Crossref]
  • [37] Gionchetti P., Rizzello F., Venturi A., Ferretti M., Brignola C., Peruzzo S., et al., Long-term efficacy of bismuth carbomer enemas in patients with treatment-resistant chronic pouchitis, Aliment. Pharmacol. Ther., 1997, 11, 673–678[Crossref]
  • [38] Wischmeyer P., Pemberton J.H., Phillips S.F., Chronic pouchitis after ileal pouch-anal anastomosis: responses to butyrate and glutamine suppositories in a pilot study, Mayo Clin. Proc., 1993, 68, 978–981 [Crossref]
  • [39] Levin K.E., Pemberton J.H., Phillips S.F., Zinsmeister A.R., Pezim M.E., Role of oxygen free radicals in the etiology of pouchitis. Dis. Colon Rectum, 1992, 35, 452–456[Crossref]
  • [40] Hurst R.D., Molinari M., Chung T.P., Rubin M., Michelassi F., Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy, Arch. Surg., 1996, 131, 497–500 [Crossref]
  • [41] Rahimi R., Nikfar S., Rezaie A., Abdollahi M., A metaanalysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: evidence for prevention of disease relapse and maintenance of remission, Arch. Med. Sci. 2008, 4, 185–190
  • [42] Rahimi R., Nikfar S., Rahimi F., Elahi B., Derakhshani S., Vafaie M., et al., A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn’s disease, Dig. Dis. Sci., 2008, 53, 2524–2531[Crossref][WoS]
  • [43] Nikfar S., Rahimi R., Rahimi F., Derakhshani S., Abdollahi M., Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials, Dis. Col. Rectum, 2008, 51, 1775–1780[Crossref]
  • [44] Fric P., Probiotics and prebiotics; resistance of a therapeutic principle, Cent. Eur. J. Med., 2007, 2, 237–270.[WoS][Crossref]
  • [45] Rahimi R., Nikfar S., Abdollahi M., Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: A meta-analysis of randomized controlled trials, Arch. Med. Sci., 2008, 4, 71–76
  • [46] Talley N.J., Newer antidepressants in irritable bowel syndrome: what is the evidence? Arch. Med. Sci., 2008, 4, 77–78.
  • [47] Rahimi R., Nikfar S., Abdollahi M., Meta-analysis technique confirms the effectiveness of anti-TNF-a in the management of active ulcerative colitis when administered in combination with corticosteroids, Med. Sci. Monit., 2007, 13, PI13–PI18
  • [48] Rahimi, R., Nikfar, S., Abdollahi M., Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn’s disease? A systematic meta-analysis of controlled clinical trials, Biomed. Pharmacother., 2007, 61, 75–80[WoS][Crossref]
  • [49] Hosseini-Tabatabaei A., Abdollahi M., Potassium channel openers and improvement of toxic stress: do they have role in the management of inflammatory bowel disease? Inflamm. Allergy Drug Targets, 2008, 7, 129–135[Crossref]
  • [50] Rezaie A., Parker R.D., Abdollahi M., Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig. Dis. Sci., 2007, 52, 2015–2021[Crossref][WoS]
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.